EA201692375A1 - Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов - Google Patents
Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответовInfo
- Publication number
- EA201692375A1 EA201692375A1 EA201692375A EA201692375A EA201692375A1 EA 201692375 A1 EA201692375 A1 EA 201692375A1 EA 201692375 A EA201692375 A EA 201692375A EA 201692375 A EA201692375 A EA 201692375A EA 201692375 A1 EA201692375 A1 EA 201692375A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- vaccines
- methods
- immune responses
- antibody
- application
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 241001591005 Siga Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000008348 humoral response Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000013507 mapping Methods 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Physiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
Abstract
Настоящее изобретение относится к композициям адъюванта, вакцинам, конструкциям для получения композиций адъювантов и вакцин и способам применения композиций адъюванта и вакцин для усиления иммунных ответов у индивидуумов. В частности, вызывают быстрый гуморальный ответ на вакцину, включая IgG (в кровотоке) и sIgA (слизистый секреторный IgA). Адъюванты и вакцины можно применять для подкожного введения или введения через слизистые оболочки, делающего возможной дешевую, эффективную вакцинацию индивидуумов. Кроме того, настоящее изобретение относится к способу эпитопного картирования для быстрой идентификации антигенных эпитопов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462008178P | 2014-06-05 | 2014-06-05 | |
PCT/US2015/034229 WO2015187969A2 (en) | 2014-06-05 | 2015-06-04 | Antibody guided vaccines and methods of use for generation of rapid mature immune responses |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201692375A1 true EA201692375A1 (ru) | 2017-04-28 |
Family
ID=54767591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692375A EA201692375A1 (ru) | 2014-06-05 | 2015-06-04 | Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов |
Country Status (16)
Country | Link |
---|---|
US (1) | US20170196971A1 (ru) |
EP (1) | EP3151858A4 (ru) |
JP (1) | JP2017523136A (ru) |
KR (1) | KR20170007853A (ru) |
CN (1) | CN106535932A (ru) |
AR (1) | AR100740A1 (ru) |
AU (1) | AU2015269415A1 (ru) |
BR (1) | BR112016028418A2 (ru) |
CA (1) | CA2951041A1 (ru) |
CL (1) | CL2016003107A1 (ru) |
EA (1) | EA201692375A1 (ru) |
MX (1) | MX2016016080A (ru) |
PH (1) | PH12016502389A1 (ru) |
SG (1) | SG11201609965XA (ru) |
TW (1) | TW201613638A (ru) |
WO (1) | WO2015187969A2 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3097926B1 (en) * | 2007-11-01 | 2019-10-02 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
AR108688A1 (es) | 2016-05-03 | 2018-09-19 | Univ Arkansas | Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso |
US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
EP3470424A4 (en) * | 2016-06-08 | 2020-03-04 | Shanghai Jiaotong University School of Medicine | SEQUENCE OF HEAVY CHAIN CONSTANT ANTIBODY REGION TO INCREASE AGONIST-ANTIBODY ACTIVITY |
CN115956089A (zh) | 2020-05-04 | 2023-04-11 | 加利福尼亚大学董事会 | 抑制性抗enpp1抗体 |
CN117164714B (zh) * | 2023-10-08 | 2024-04-23 | 北京奇迈永华生物科技有限公司 | 一种靶向bcma的抗体及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6934600A (en) * | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
WO2010053987A2 (en) * | 2008-11-04 | 2010-05-14 | Duke University | Monoclonal antibody production in b cells and uses therof |
CN106432493B (zh) * | 2009-03-10 | 2020-01-31 | 贝勒研究院 | 抗-cd40抗体及其用途 |
KR101881611B1 (ko) * | 2010-06-09 | 2018-07-25 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 캄필로박터 감염을 감소시키기 위한 백신 및 방법 |
WO2012041635A1 (en) * | 2010-09-29 | 2012-04-05 | Universite De Liege | Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
-
2015
- 2015-06-04 JP JP2016571188A patent/JP2017523136A/ja active Pending
- 2015-06-04 KR KR1020177000029A patent/KR20170007853A/ko unknown
- 2015-06-04 EA EA201692375A patent/EA201692375A1/ru unknown
- 2015-06-04 MX MX2016016080A patent/MX2016016080A/es unknown
- 2015-06-04 WO PCT/US2015/034229 patent/WO2015187969A2/en active Application Filing
- 2015-06-04 BR BR112016028418A patent/BR112016028418A2/pt not_active Application Discontinuation
- 2015-06-04 CA CA2951041A patent/CA2951041A1/en not_active Abandoned
- 2015-06-04 AU AU2015269415A patent/AU2015269415A1/en not_active Abandoned
- 2015-06-04 EP EP15802830.8A patent/EP3151858A4/en not_active Withdrawn
- 2015-06-04 AR ARP150101782A patent/AR100740A1/es unknown
- 2015-06-04 SG SG11201609965XA patent/SG11201609965XA/en unknown
- 2015-06-04 CN CN201580035340.0A patent/CN106535932A/zh active Pending
- 2015-06-04 US US15/316,421 patent/US20170196971A1/en not_active Abandoned
- 2015-06-05 TW TW104118436A patent/TW201613638A/zh unknown
-
2016
- 2016-11-29 PH PH12016502389A patent/PH12016502389A1/en unknown
- 2016-12-02 CL CL2016003107A patent/CL2016003107A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20170196971A1 (en) | 2017-07-13 |
CN106535932A (zh) | 2017-03-22 |
EP3151858A2 (en) | 2017-04-12 |
AR100740A1 (es) | 2016-10-26 |
EP3151858A4 (en) | 2018-01-17 |
WO2015187969A2 (en) | 2015-12-10 |
CA2951041A1 (en) | 2015-12-10 |
WO2015187969A3 (en) | 2016-01-21 |
TW201613638A (en) | 2016-04-16 |
JP2017523136A (ja) | 2017-08-17 |
SG11201609965XA (en) | 2016-12-29 |
AU2015269415A1 (en) | 2017-01-05 |
BR112016028418A2 (pt) | 2018-02-20 |
MX2016016080A (es) | 2017-05-09 |
KR20170007853A (ko) | 2017-01-20 |
PH12016502389A1 (en) | 2017-02-20 |
CL2016003107A1 (es) | 2017-05-19 |
AU2015269415A2 (en) | 2017-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201692375A1 (ru) | Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов | |
WO2017096341A3 (en) | Adenovirus-vectored multivalent vaccine | |
WO2017210579A8 (en) | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu | |
EA200701786A1 (ru) | Поливалентная противогриппозная иммуногенная композиция | |
MX2015008847A (es) | Composiciones inmunogenicas de virus de influenza y usos de las mismas. | |
MX363529B (es) | Vesículas de membrana externa. | |
MX2022002106A (es) | Formulaciones de vacuna de vial unico. | |
NZ708065A (en) | Novel mucosal adjuvants and delivery systems | |
NZ729519A (en) | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin | |
WO2015175355A8 (en) | Compositions and methods of enhancing immunogenicity of polysaccharide-protein conjugates | |
PH12015501716A1 (en) | Anti-mycoplasma spp. subunit vaccine | |
EA201892735A1 (ru) | Состав вакцины против hiv | |
MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
PH12014501795B1 (en) | Rotavirus subunit vaccines and methods of making and use thereof | |
WO2016191641A3 (en) | Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens | |
MX2021007502A (es) | Formulaciones y métodos de vacuna de norovirus. | |
WO2018066999A3 (en) | Chimeric enterovirus virus-like particles | |
DK3016673T3 (da) | Pattedyrsmælkeosteopontin til forbedring af immunreaktion | |
WO2016120596A8 (en) | Multi-epitopic construct | |
ZA202110437B (en) | Compositions and methods of manufacturing trivalent filovirus vaccines | |
WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
MX2022000525A (es) | Vacunas contra la ehrlichia y composiciones inmunogenicas. | |
Golshani et al. | A RECOMBINANT SUBUNIT VACCINE BASED ON THE L7/L12 AND TOMP31 PROTEINS INDUCES PROTECTION AGAINST BRUCELLA INFECTION IN BALB/C MICE | |
池田貴裕 | Comparison of Mucosal Immune Response after Oral, Nasal or Sublingual Immunization with an Outer Membrane Protein of Porphyromonas gingivalis | |
MX2021001641A (es) | Identificacion de proteinas inmunogenicas para el control de ectoparasitos. |